KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma-Reference-Cited by-同舟云学术

KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma

Published:2022 Issue:6 Volume:18 Page:506-519
ISSN:2515-4184
Container-title:Molecular Omics
language:en
Short-container-title:Mol. Omics

Author:

Zhang Mengjun¹,Liu Yuan¹,Hou Siyu²,Wang Yiru¹,Wang Can¹,Yin Yue¹,Chen Xiuwei¹^ORCID

Affiliation:

1. Harbin Medical University Cancer Hospital, Harbin, China

2. Department of Obstetrics and Gynecology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

Abstract

The step-by-step research process of this research. After scientific bioinformatics analysis and rigorous experimental verification, KDM4B was finally found to be a potential novel prognostic biomarker for UCEC.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Genetics,Molecular Biology,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/MO/D1MO00287B

Reference38 articles.

1. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

3. Integrated genomic characterization of endometrial carcinoma

4. Fertility-Sparing Therapy in Young Women With Endometrial Cancer

5. Advances in histone demethylase KDM4 as cancer therapeutic targets

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KDM4B: A promising oncology therapeutic target;Cancer Science;2023-11-03

2. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods;Frontiers in Molecular Biosciences;2023-06-09

3. The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy;Frontiers in Immunology;2023-01-11

4. RPP40 is a prognostic biomarker and correlated with tumor microenvironment in uterine corpus endometrial carcinoma;Frontiers in Oncology;2022-08-24